Question 1

What insurance policy changes affect CPT 38215?

Accepted Answer

There are 4 tracked policy changes affecting CPT 38215, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Question 2

Which payers have updated policy for CPT 38215?

Accepted Answer

Payers that have issued tracked updates for CPT 38215 include: Aetna, Blue Cross & Blue Shield of Mississippi.

Question 3

How do I get notified when CPT 38215 policy changes?

Accepted Answer

Create a free account at PolicyChanges.app and save a search filtered to CPT 38215. You will receive a daily digest email whenever a new policy change references this code.

Question 4

Why do payers change policies for CPT 38215?

Accepted Answer

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

38215 Insurance Policy Changes

Bendamustine Products (CPB 0875, reviewed 2026-02-24)

Betibeglogene Autotemcel (Zynteglo) (CPB 1016, reviewed 2025-12-31)

Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia

Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas